Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

android tablet pc

Home > Press > Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors

Richard Hawkins, Founder and Former CEO of PPD Pharmaco, Joins Board

Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors

Austin, TX | Posted on November 8th, 2010

Savara Inc., an inhalation product development company, today announced that it has appointed Richard Hawkins to its Board of Directors.

In 1983 Mr. Hawkins founded Pharmaco and as Chairman, President and CEO he guided the growth of that organization to over 700 employees. It eventually became PPD Pharmaco, one of the largest clinical contract research organizations in the world. Since Pharmaco, he has served in various capacities in numerous startup companies, including Sensus Drug Development Corporation, which was sold to Pfizer; Covance Biotechnology Services, which was sold to Akzo Nobel Inc. in early 2001; and LoopOne, Inc., which was sold to Neopost in May 2001.

"We are honored to have someone with Mr. Hawkins' track record join the Board of Directors," said Rob Neville, CEO of Savara. "We now have the board and executive team in place to move our lead product into the clinic."

Mr. Hawkins currently serves on the Board of Directors for SciClone Pharmaceuticals Inc. and on the Board for Cytori Therapeutics Inc. Recently he co-founded and acted as CEO, President and Chairman of Austin-based LabNow. In 2006 he was named one the top 10 Life Sciences CEO's in Texas by the Texas Healthcare & Bioscience Institute.

"I have been following Savara for some time and am very impressed with their technologies and progress," said Mr. Hawkins. "It is clear that this team is passionate, focused and knows how to execute."

Mr. Hawkins is a member of the National Ernest and Young Entrepreneur of the Year Hall of Fame and received the Ernest and Young 1991 Service Industry Award - Austin Region.


About Savara Inc.
Savara Inc. is an inhalation drug development company developing next-generation respiratory therapeutics utilizing its proprietary NanoCluster dry-powder formulation technology. Savara's NanoCluster technology is currently available for evaluation and licensing.

For more information, please click here

Taneli Jouhikainen
(888) 302-4876

Rob Neville
(888) 302-4876

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

The Hiden EQP Plasma Diagnostic with on-board MCA July 22nd, 2014

Iran to Hold 3rd Int'l Forum on Nanotechnology Economy July 22nd, 2014

Nanometrics Announces Upcoming Investor Events July 22nd, 2014


Nanometrics Announces Upcoming Investor Events July 22nd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014

Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014

SEMATECH Appoints Satyavolu Papa Rao to Lead Process Technology May 13th, 2014

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE